Shunichi Shiozawa

Prof. Dr. Shunichi Shiozawa

orcid

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2000 in European Journal of Biochemistry
Verified
Journal Article
Open access
PDF file
TSToshiyuki Sakaki
Toshiyuki Sakaki
NSNatsumi Sawada
Natsumi Sawada
KKKoichiro Komai
Koichiro Komai
Shunichi ShiozawaShunichi Shiozawa
Shunichi Shiozawa
SYSachiko Yamada
Sachiko Yamada
KIKuniyo Inouye
Kuniyo Inouye
Human 25‐hydroxyvitamin D3 (25(OH)D3) 24‐hydroxylase (CYP24) cDNA was expressed in Escherichia coli, and its enzymatic and spectral properties were revealed. The reconstituted system containing the membrane fraction prepared from recombinant E. coli cells, adrenodoxin and adrenodoxin reductase was examined for the metabolism of 25(OH)D3, 1α,25(OH)2D3 and their related compounds. Human CYP24 demonstrated a remarkable metabolism consisting of both C‐23 and C‐24 hydroxylation pathways towards both 25(OH)D3 and 1α,25(OH)2D3, whereas rat CYP24 showed almost no C‐23 hydroxylation pathway [Sakaki, T. Sawada, N. Nonaka, Y. Ohyama, Y. & Inouye, K. (1999) Eur. J. Biochem. 262, 43–48]. HPLC analysis and mass spectrometric analysis revealed that human CYP24 catalyzed all the steps of the C‐23 hydroxylation pathway from 25(OH)D3 via 23S,25(OH)2D3, 23S,25,26(OH)3D3 and 25(OH)D3‐26,23‐lactol to 25(OH)D3‐26,23‐lactone in addition to the C‐24 hydroxylation pathway from 25(OH)D3 via 24R,25(OH)2D3, 24‐oxo‐25(OH)D3, 24‐oxo‐23S,25(OH)2D3 to 24,25,26,27‐tetranor‐23(OH)D3. On 1α,25(OH)2D3 metabolism, similar results were observed. These results strongly suggest that the single enzyme human CYP24 is greatly responsible for the metabolism of both 25(OH)D3 and 1α,25(OH)2D3. We also succeeded in the coexpression of CYP24, adrenodoxin and NADPH‐adrenodoxin reductase in E. coli. Addition of 25(OH)D3 to the recombinant E. coli cell culture yielded most of the metabolites in both the C‐23 and C‐24 hydroxylation pathways. Thus, the E. coli expression system for human CYP24 appears quite useful in predicting the metabolism of vitamin D analogs used as drugs.

1 April 1992 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
Shunichi ShiozawaShunichi Shiozawa
Shunichi Shiozawa
YKYasuo Kuroki
Yasuo Kuroki
MKMitsunori Kim
Mitsunori Kim
SHShunsei Hirohata
Shunsei Hirohata
TOTetsuya Ogino
Tetsuya Ogino
Objective. Since the level of interferon‐α (IFNα) is increased in the sera of patients with active systemic lupus erythematosus (SLE) and is detectable in the cerebrospinal fluid (CSF) of some SLE patients with neuropsychiatric manifestations, we investigated the contribution of IFNα to the pathogenesis of the neuropsychiatric manifestations of SLE.Methods. IFNα levels were quantitated by radioimmunoassay in CSF and serum samples from 17 SLE patients with neuropsychiatric manifestations and 28 patients with SLE alone or SLE and other neurologic disorders.Results. Levels of IFNα were increased in the CSF of 5 of 6 patients with lupus psychosis, and in 4 of these 5 patients, the levels in CSF were higher than those in serum. IFNα levels decreased when the manifestation of lupus psychosis subsided. In contrast, IFNα levels in CSF samples from patients with seizures alone were not increased. One patient with lupus psychosis died of complications of generalized seizures resulting from the SLE. At autopsy, we investigated whether IFNα protein or messenger RNA was detectable in the subject's brain. IFNα protein was immunohistochemically demonstrated in the neurons and in the microglia (focal accumulation), features not present in the brain tissues of subjects who died of other diseases.Conclusion. These findings support the hypothesis that IFNα, possibly synthesized in the brain, is the cause of the manifestation of psychosis in patients with SLE.

28 February 2006 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
NTNozomi Takami
Nozomi Takami
KOKayo Osawa
Kayo Osawa
YMYasushi Miura
Yasushi Miura
KKKoichiro Komai
Koichiro Komai
MTMariko Taniguchi
Mariko Taniguchi
Shunichi ShiozawaShunichi Shiozawa
Shunichi Shiozawa
Objective: To examine the promoter activity and protein expression of the death receptor 3 gene DR3, a member of the apoptosis‐inducing Fas gene family, with particular reference to the methylation status of its promoter region in rheumatoid arthritis (RA).Methods: Genomic DNA was prepared from peripheral blood mononuclear cells obtained from healthy individuals and from patients with RA and synovial cells obtained from patients with RA and osteoarthritis. The methylation status of the DR3 promoter was analyzed by bisulfite genomic sequencing and methylation‐specific polymerase chain reaction techniques. Gene promoter activity and protein expression were examined using the luciferase reporter and Western blotting techniques.Results: The promoter region of the DR3 gene contained many CpG motifs, including one CpG island that was specifically hypermethylated in synovial cells from patients with RA. Promoter assays showed that the promoter CpG island was essential for the transactivation of the DR3 gene and that forced hypermethylation of the CpG island with the bacterial methylase Sss I in vitro resulted in inhibition of the DR3 gene expression. Furthermore, the expression of DR‐3 protein was down‐modulated in association with methylation of the promoter CpG island in RA synovial cells.Conclusion: The CpG island in the DR3 gene promoter was specifically methylated to down‐modulate the expression of DR‐3 protein in rheumatoid synovial cells, which may provide resistance to apoptosis in RA synovial cells.

1 January 1985 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
SSShinichi Shimizu
Shinichi Shimizu
Shunichi ShiozawaShunichi Shiozawa
Shunichi Shiozawa
KSKazuko Shiozawa
Kazuko Shiozawa
SIShigeaki Imura
Shigeaki Imura
TFTakuo Fujita
Takuo Fujita
The pathogenesis of periarticular osteopenia in rheumatoid arthritis (RA) was investigated by histomorphometry on juxtaarticular bone removed during joint surgery. Twenty areas from 12 RA patients were compared with 14 areas from 6 osteoarthritis (OA) patients. There was no difference between the 2 groups in the percent of total bone volume. However, increased bone formation was suggested by an increase in the percent of active osteoid surface in RA compared with that in OA. Bone resorption was also increased in RA, as evidenced by increases versus OA in percent total resorptive surface, percent active resorptive surface, and number of osteoclasts. These results demonstrate increased turnover of bone in RA, especially in the resorptive phase of the periarticular trabecular bone. It is proposed that soluble factor(s) synthesized in the contiguous rheumatoid synovium may be transferred to the periarticular bone space, stimulating osteoclasts to resorb bone.

1 April 1983 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
Shunichi ShiozawaShunichi Shiozawa
Shunichi Shiozawa
KSKazuko Shiozawa
Kazuko Shiozawa
TFTakuo Fujita
Takuo Fujita
The early phase of cartilage destruction by active cellular pannus in rheumatoid joints was observed under light and electron microscopy. In the early phase of pannus formation, cartilage was covered by several layers of fibroblast‐like cells. This was also the case at the advancing edge of the pannus. Invasion of the cartilage by macrophage‐like cells has been observed to start beneath this layer. Observations under electron microscope demonstrated that the main cells participating in the cartilage destruction at the cartilage‐pannus junction were either fibroblast‐like or macrophage‐like cells, and suggested the possibility that these two types of cells were derived from synovial type A and type B cells. Morphologic observations also suggested a possibility of transformation of the fibroblast‐like cell into the macrophage‐like cell at the cartilage‐pannus junction.

15 May 2009 in Cell Cycle
Verified
Journal Article
Closed access
PDF file
Shunichi ShiozawaShunichi Shiozawa
Shunichi Shiozawa
KTKen Tsumiyama
Ken Tsumiyama
C-Fos/AP-1 controls the expression of inflammatory cytokines and matrix-degrading matrix metalloproteinases (MMPs) important in arthritis via promoter AP-1 binding motif. Among inflammatory cytokines, IL-1β is the most important inducer of a variety of MMPs, and mainly responsible for cartilage breakdown and osteoclastogenesis. IL-1β and c-Fos/AP-1 influence each other’s gene expression and activity, resulting in an orchestrated cross-talk that is crucial to arthritic joint destruction, where TNFα can act synergistically with them. While how to stop the degradation of bone and cartilage, i.e., to control MMP, has long been the central issue in the research of rheumatoid arthritis (RA), selective inhibition of c-Fos/AP-1 does resolve arthritic joint destruction. Thus, the blockade of IL-1β and/or c-Fos/AP-1 can be promising as an effective therapy for rheumatoid joint destruction in addition to the currently available TNFα blocking agents that act mainly on arthritis.